Roobol, M.J.

cancer prostate prostate cancer screening biopsy study patient erspc result european randomized study antigen value round european mortality level treatment group interval score detection trial rotterdam table number randomized prostate-speci fic antigen control diagnosis roobol analysis volume disease control arm model urology cohort gleason death follow-up population outcome schroder surveillance prostate cancer screening schroder fh effect prostate-speci psa level stage signi roobol mj incidence tumor screen characteristic prostate biopsy difference speci nomogram screening round screening arm ficant netherland serum range rectal examination centre interval cancers prostate volume tumour center prostatectomy psa test reduction prostate cancer mortality sensitivity prostate-specific pca 3 prostate-specific antigen